Disease Information

General Information of the Disease (ID: DIS00317)

• Name: Hepatic fibrosis/cirrhosis
• ICD: ICD-11: DB93

Type(s) of Resistant Mechanism of This Disease

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Artenimol

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: H19, imprinted maternally expressed transcript (H19) [1]

• Resistant Disease: Hepatic fibrosis [ICD-11: DB93.0]
• Molecule Alteration: Up-regulation; Interaction
• Resistant Drug: Artenimol
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HSC cells; N.A.; .; N.A.
• Experiment for Molecule Alteration: Knockdown assay
• Mechanism Description: LncRNA-H19 induces hepatic stellate cell activation via upregulating alcohol dehydrogenase III-mediated retinoic acid signals.

Investigative Drug(s) 2 drug(s) in total

Carbon tetrachloride

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [2]

• Resistant Disease: Hepatic fibrosis [ICD-11: DB93.0]
• Molecule Alteration: Down-regulation; Interaction
• Resistant Drug: Carbon tetrachloride
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HSC cells; N.A.; .; N.A.
• In Vivo Model: Rat hepatic fibrosis model; Rattus norvegicus
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Dual luciferase assay; RNA pull down assay
• Mechanism Description: LncRNA GAS5/miR-23a may bring molecular targets for hepatic fibrosis therapy.LncRNA GAS5 restrains CCl4-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway.

Lipopolysaccharide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Taurine up-regulated 1 (TUG1) [3]

• Resistant Disease: Hepatic cirrhosis [ICD-11: DB93.1]
• Molecule Alteration: Up-regulation; Interaction
• Resistant Drug: Lipopolysaccharide
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: LSECs; Liver; Homo sapiens (Human); CVCL_QY34
• Experiment for Molecule Alteration: Knockdown assay; Overexpression assay; qRT-PCR; Western bloting analysis; Co-immunofluorescence staining; Immunohistochemical assay; RNA-seq; Luciferase assay; FISH assay; RIP experiments assay; ELISA assay
• Experiment for Drug Resistance: WST assay; Flow cytometry assay; Transwell assay
• Mechanism Description: TUG1 promotes LPS-induced autophagy and EndMT of LSECs by functioning as an endogenous sponge for miR-142-3p and promoting the expression of A TG5. LPS and miR-142-3p are potential diagnostic and therapeutic targets in cirrhosis.

References

• Ref 1: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.
• Ref 2: lncRNA GAS5 restrains CCl(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathwayAm J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550. doi: 10.1152/ajpgi.00249.2018. Epub 2019 Feb 8.
• Ref 3: Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibitionAging (Albany NY). 2019 Sep 18;11(18):7553-7569. doi: 10.18632/aging.102271. Epub 2019 Sep 18.